KELUN-BIOTECH ANNOUNCES BREAKTHROUGH THERAPY DESIGNATION GRANTED IN CHINA FOR SACITUZUMAB TIRUMOTECAN (SAC-TMT) IN COMBINATION WITH IMMUNOTHERAPY PEMBROLIZUMAB FOR FIRST-LINE TREATMENT OF PD-L1-POSITIVE NSCLC

Reuters · 6d ago

Please log in to view news